Cardiogenic shock cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Cost-Effectiveness== | ==Cost-Effectiveness== | ||
Attending to the fact that cardiogenic shock is a lethal condition, with a high mortality rate, if not diagnosed early and treatment started in the shortest time-span possible, an aggressive diagnostic and therapeutic approach are of uttermost importance, therefore justifying the costs involved in the procedures. | Attending to the fact that cardiogenic shock is a lethal condition, with a high [[mortality rate]], if not [[diagnosis|diagnosed]] early and [[therapy|treatment]] started in the shortest time-span possible, an aggressive [[diagnostic]] and [[therapeutic]] approach are of uttermost importance, therefore justifying the costs involved in the procedures. | ||
==References== | ==References== | ||
Revision as of 22:14, 30 May 2014
|
Cardiogenic Shock Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiogenic shock cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Cardiogenic shock cost-effectiveness of therapy |
|
Risk calculators and risk factors for Cardiogenic shock cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Cost-Effectiveness
Attending to the fact that cardiogenic shock is a lethal condition, with a high mortality rate, if not diagnosed early and treatment started in the shortest time-span possible, an aggressive diagnostic and therapeutic approach are of uttermost importance, therefore justifying the costs involved in the procedures.